Primary cutaneous indolent B-cell lymphomas – a retrospective multicenter analysis and a review of literature

Olszewska-Szopa, Magdalena; Sobas, Marta; Laribi, Kamel; Pérez, Laura Bao; Drozd‐Sokołowska, Joanna; Subocz, Edyta; Joks, Monika; Zduniak, Krzysztof; Gajewska, Małgorzata; Nałęcz, Anna Kulikowska de; Romejko‐Jarosińska, Joanna; Kumiega, Beata; Waszczuk‐Gajda, Anna; Wróbel, Tomasz; Czyż, Anna

doi:10.1080/0284186x.2021.1956689

Cited by 9 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our search determined that nine new studies investigating the role of 18 F-FDG PET/CT in PCLs have been published between 2015 and 2021 (Table 3) [6,12,[18][19][20][21][22][23][24]. These studies were screened and selected utilizing Google scholar search engine.…”

Section: Methodsmentioning

confidence: 99%

“…After diagnosis of PCL, subsequent steps in management of disease vary based on whether a cutaneous lymphoma is classified as "indolent" or "aggressive" (Table 1) [2]. Indolent lymphomas in the early stage may be imaged with conventional methods such as a chest X-ray or ultrasound of the abdomen and superficial lymph nodes [12]. CT scan is the recommended imaging modality to assess higher stage PCL lesions which are not 18 F-FDG-avid.…”

Section: Managing Indolent Versus Aggressive Pclmentioning

confidence: 99%

“…CT scan is the recommended imaging modality to assess higher stage PCL lesions which are not 18 F-FDG-avid. Whole-body 18 F-FDG-PET/CT is strongly recommended for more aggressive or late-stage cutaneous lymphomas such as PC-DLBCL-leg type, PC-FCL, and Sézary syndrome [12]. Staging of disease should be performed annually at minimum to monitor progress of disease.…”

Section: Managing Indolent Versus Aggressive Pclmentioning

confidence: 99%

“…The prognosis of all NHLs is predicted using the International Prognostic Index (IPI), which accounts for patient age, LDH levels, location of lesions, and extent of skin involvement [13][14][15]. Subtypes of PCL have individualized criteria to generate a prognostic score specific for that subtype of disease [12]. The IPI score, used to determine treatment in aggressive primary cutaneous NHL subtypes such as PC-DLBCL-leg type and primary cutaneous peripheral T-cell lymphoma, considers updated Ann Arbor criteria, disease stage, serum LDH, hemoglobin, patient age, and patient "performance status" [15][16][17].…”

Section: Managing Indolent Versus Aggressive Pclmentioning

confidence: 99%

“…Other imaging modalities such as radiography, ultrasound, CT, and magnetic resonance imaging (MRI) are used in combination with physicians' physical assessment findings to fully stage PCL. 18 F-FDG PET/CT is not sensitive for cutaneous lesions with low metabolic activity, which is commonly a characteristic of early-stage PCL and indolent subtypes of PCL [12,19,24,26]. While 18 F-FDG PET/CT has not been shown to effectively detect early-stage cutaneous PCL lesions, it is, however, very sensitive for highly metabolically active cutaneous and visceral PCL lesions in aggressively presenting late-stage disease (Fig.…”

Section: F-fdg Pet/ctmentioning

confidence: 99%

See 4 more Smart Citations

The role of 18F-FDG PET/CT in primary cutaneous lymphoma: an educational review

et al. 2023

View full text Add to dashboard Cite

Introduction Primary cutaneous lymphoma (PCL) is a cutaneous non-Hodgkin’s lymphoma that originates in the skin and lacks extracutaneous spread upon initial diagnosis. The clinical management of secondary cutaneous lymphomas is different from that of PCLs, and earlier detection is associated with better prognosis. Accurate staging is necessary to determine the extent of disease and to choose the appropriate treatment. The aim of this review is to investigate the current and potential roles of 18F- fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG PET/CT) in the diagnosis, staging, and monitoring of PCLs. Methods A focused review of the scientific literature was performed using inclusion criteria to filter results pertaining to human clinical studies performed between 2015 and 2021 that analyzed cutaneous PCL lesions on 18F PET/CT imaging. Results & Conclusion A review of 9 clinical studies published after 2015 concluded that 18F-FDG PET/CT is highly sensitive and specific for aggressive PCLs and proved valuable for identifying extracutaneous disease. These studies found 18F-FDG PET/CT highly useful for guiding lymph node biopsy and that imaging results influenced therapeutic decision in many cases. These studies also predominantly concluded that 18F-FDG PET/CT is more sensitive than computed tomography (CT) alone for detection of subcutaneous PCL lesions. Routine revision of nonattenuation-corrected (NAC) PET images may improve the sensitivity of 18F-FDG PET/CT for detection of indolent cutaneous lesions and may expand the potential uses of 18F-FDG PET/CT in the clinic. Furthermore, calculating a global disease score from 18F-FDG PET/CT at every follow-up visit may simplify assessment of disease progression in the early clinical stages, as well as predict the prognosis of disease in patients with PCL.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Managing Indolent Versus Aggressive Pclmentioning

confidence: 99%

Section: Managing Indolent Versus Aggressive Pclmentioning

confidence: 99%

Section: Managing Indolent Versus Aggressive Pclmentioning

confidence: 99%

Section: F-fdg Pet/ctmentioning

confidence: 99%

See 3 more Smart Citations

The role of 18F-FDG PET/CT in primary cutaneous lymphoma: an educational review

et al. 2023

View full text Add to dashboard Cite

show abstract

An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma

Elieh‐Ali‐Komi

Maurer

et al. 2023

Clin Exp Med

View full text Add to dashboard Cite

Primary cutaneous T-cell lymphomas (CTCL), which include mycosis fungoides (MF) and Sézary syndrome (SS), are a group of lymphoproliferative disorders characterized by clonal accumulation of neoplastic T-lymphocytes in the skin. Severe pruritus, one of the most common and distressing symptoms in primary CTCL, can significantly impair emotional well-being, physical functioning, and interpersonal relationships, thus greatly reducing quality of life. Unfortunately, effectively managing pruritus remains challenging in CTCL patients as the underlying mechanisms are, as of yet, not fully understood. Previous studies investigating the mechanisms of itch in CTCL have identified several mediators and their corresponding antagonists used for treatment. However, a comprehensive overview of the mediators and receptors contributing to pruritus in primary CTCL is lacking in the current literature. Here, we summarize and review the mediators and receptors that may contribute to pruritus in primary CTCL to explore the mechanisms of CTCL pruritus and identify effective therapeutic targets using the PubMed and Web of Science databases. Studies were included if they described itch mediators and receptors in MF and SS. Overall, the available data suggest that proteases (mainly tryptase), and neuropeptides (particularly Substance P) may be of greatest interest. At the receptor level, cytokine receptors, MRGPRs, and TRP channels are most likely important. Future drug development efforts should concentrate on targeting these mediators and receptors for the treatment of CTCL pruritus.

show abstract

Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas

Hu,

Scheffel,

Frischbutter

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Patients with primary cutaneous T-cell lymphoma (CTCL) often experience severe and difficult-to-treat pruritus that negatively affects their quality of life (QoL). However, the mechanisms of pruritus in CTCL, including mycosis fungoides (MF), remain largely unknown, and detailed characteristics of CTCL-associated pruritus is not fully elucidated. To characterize pruritus in CTCL, cutaneous B-cell lymphoma (CBCL), and large plaque parapsoriasis (LPP), and to identify potential itch mediators involved in the pathogenesis of pruritus in CTCL patients. Clinical data and blood samples were collected from 129 healthy subjects and 142 patients. Itch intensity, QoL impairment, psychological distress, and sleep quality were assessed using validated questionnaires and instruments. Blood levels of BDNF, CCL24, GRP, IL-31, IL-33, sST2, substance P, TSLP, tryptase and total IgE were measured using ELISA or ImmunoCAP. Pruritus was prevalent in CTCL, LPP and CBCL patients, with higher prevalence and severity observed in CTCL. In CTCL, pruritus correlated with significant impairment in QoL, sleep, psychological distress. Compared to healthy controls, elevated levels of IL-31, IL-33, substance P, total IgE, tryptase, and TSLP were found in MF patients. A comparison of MF patients with and without pruritus revealed higher levels of IL-31, substance P, GRP, and CCL24 in the former. Itch intensity positively correlated with IL-31, GRP, CCL24, and tryptase levels. Pruritus significantly burdens CTCL patients, necessitating appropriate therapeutic management. Our findings suggest that various non-histaminergic mediators such as tryptase and IL-31 could be explored as novel therapeutic targets for managing pruritus in MF patients.

show abstract

Primary cutaneous indolent B-cell lymphomas – a retrospective multicenter analysis and a review of literature

Cited by 9 publications

References 23 publications

The role of 18F-FDG PET/CT in primary cutaneous lymphoma: an educational review

The role of 18F-FDG PET/CT in primary cutaneous lymphoma: an educational review

An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma

Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas

Contact Info

Product

Resources

About